Core Insights - 罗欣药业 reported its Q3 2025 financial results, highlighting significant institutional investor interest with a total of 4.35 billion shares held, representing 39.96% of the company's total equity [1] Institutional Holdings - As of October 27, 2025, seven institutional investors disclosed their holdings in 罗欣药业, with a combined ownership increase of 0.80 percentage points from the previous quarter [1] - Major institutional investors include 山东罗欣控股有限公司, 上海中珏私募基金管理有限公司, ALLY BRIDGE FLAGSHIP LX (HK) LIMITED, and others [1] Public Fund Activity - In this reporting period, 22 public funds were disclosed, including 富国稳健增长混合A, 华宝创新优选混合, and others, indicating continued interest from public investment vehicles [1] Foreign Investment - One foreign fund, 香港中央结算有限公司, increased its holdings by 1.39% compared to the previous period, reflecting a positive sentiment from foreign investors [1]

Summary of Key Points Core Viewpoint - 罗欣药业's recent financial disclosures indicate a mixed performance in non-recurring gains and losses, with significant fluctuations over the past three years, highlighting the company's reliance on non-operational income sources [1][2]. Group 1: Financial Performance - As of October 27, 2025, 罗欣药业's stock closed at 5.31 yuan, down 0.75%, with a trading volume of 254,700 shares and a turnover of 136 million yuan [1]. - The net non-recurring gains and losses for 罗欣药业 from 2022 to the first nine months of 2025 were reported as 215,423,150.70 yuan, -22,285,473.56 yuan, -197,375,374.58 yuan, and 18,008,575.68 yuan respectively [1]. - The significant non-recurring gain in 2022 was primarily due to non-current asset disposal, amounting to 136,264,318.65 yuan, while a loss of 213,130,913.80 yuan was recorded in 2024 due to fair value changes related to the disposal of 上药罗欣 [1]. Group 2: Fund Utilization - 罗欣药业's previous fundraising efforts totaled 663,566.00 million yuan, fully utilized for acquiring a 99.65476% stake in 山东罗欣药业 [2][3]. - The asset performance post-acquisition showed a net profit of 56,450.69 million yuan in 2019, but fell short of commitments in 2020 and 2021, leading to the cancellation of 371,334,114 shares as compensation [2]. - The total assets of 罗欣药业 decreased from 721,226.54 million yuan at the end of 2019 to 497,240.24 million yuan by the end of 2024 [2].

Core Insights - The company reported a revenue of 646,173,009.72 yuan for the third quarter of 2025, representing a year-on-year growth of 3.94% [1] - The net profit attributable to shareholders of the listed company was 5,231,766.19 yuan, showing a significant year-on-year increase of 102.96% [1]

罗欣药业集团股份有限公司 章 程 | 第一节 | 股东的一般规定 | 12 | | --- | --- | --- | | 第二节 | 控股股东和实际控制人 | 16 | | 第三节 | 股东会的一般规定 | 17 | | 第四节 | 股东会的召集 | 21 | | 第五节 | 股东会的提案和通知 | 22 | | 第六节 | 股东会的召开 | 24 | | 第七节 | 股东会的表决和决议 | 27 | | 第一节 | 董事的一般规定 | 32 | | 第二节 | 董 事 会 | 36 | | 第三节 | 独立董事 | 40 | | 第四节 | 董事会专门委员会 | 42 | | 第一节 | 财务会计制度 | 46 | | 第二节 | 内部审计 | 51 | | 第三节 | 会计师事务所的聘任 | 52 | | 第一节 | 合并、分立、增资和减资 | 54 | | 第二节 | 公司解散和清算 | 56 | 第一章 总 则 第一条 为维护公司、股东、职工和债权人的合法权益，规范公司的组织和 行为，根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人 民共和国证券法》（以下简称"《证券法》"）、《中国 ...

罗欣药业集团股份有限公司 董事会议事规则 第一章 总则 第一条 为规范罗欣药业集团股份有限公司（以下简称"公司"或"本公司"） 董事会及其成员的行为，保障董事会高效运作和科学决策，根据《中华人民共和 国公司法》《中华人民共和国证券法》《深圳证券交易所股票上市规则》《深圳证 券交易所上市公司自律监管指引第 1 号—主板上市公司规范运作》及其他相关法 律、行政法规、部门规章、规范性文件和《罗欣药业集团股份有限公司章程》（以 下简称"《公司章程》"）的有关规定，特制定本规则。 第二章 董事 第二条 公司董事为自然人，有下列情形之一的，不得担任公司的董事： （一）无民事行为能力或者限制民事行为能力； （二）因贪污、贿赂、侵占财产、挪用财产或者破坏社会主义市场经济秩序， 被判处刑罚，或者因犯罪被剥夺政治权利，执行期满未逾 5 年，被宣告缓刑的， 自缓刑考验期满之日起未逾 2 年； （三）担任破产清算的公司、企业的董事或者厂长、总经理，对该公司、企 业的破产负有个人责任的，自该公司、企业破产清算完结之日起未逾 3 年； （九）法律、行政法规或部门规章规定的其他内容。 董事候选人应在知悉或理应知悉其被推举为董事候选人的第一 ...

章程修改条款对比表 | 序号 | 修改前内容 | 修改后内容 | | --- | --- | --- | | | 第一百一十二条 董事会由 6 名董 | 第一百一十二条 董事会由 7 名董事 | | | 事组成，其中独立董事 名。职工代表 3 | 组成，其中独立董事 名。职工代表董 3 | | 1 | 董事由职工代表大会、职工大会或其他 | 事 1 名，由职工代表大会、职工大会或 | | | 形式民主选举产生；其他董事由股东会 | 其他形式民主选举产生；其他董事由股 | | | 选举产生。 | 东会选举产生。 | | | 第一百三十八条 审计委员会成员 | 第一百三十八条 审计委员会成员 为 3 名，为不在公司担任高级管理人员 | | | 为 名，为不在公司担任高级管理人员 3 | | | 2 | | 的董事，其中独立董事 名，非独立董 2 | | | 的董事，其中独立董事 名，由独立董 2 | 事 名，由独立董事中会计专业人士担 | | | 事中会计专业人士担任召集人。 | 1 | | | | 任召集人。 | 罗欣药业集团股份有限公司 ...

一、前次募集资金情况 2019 年 5 月 31 日，公司第三届董事会第九次会议审议通过了《关于本次重大资产置换 及发行股份购买资产暨关联交易的议案》，2019 年 6 月 18 日，公司 2019 年度第一次临时 股东大会审议通过上述议案。根据上述议案，公司以置出资产作为对价与山东罗欣药业集团 股份有限公司（以下简称山东罗欣）股东合计持有的 99.65476%股权中的等值部分进行置换； 公司以非公开发行的股份购买重大资产置换后山东罗欣股东持有的剩余股权。此次重大资产 重组包括重大资产置换及发行股份购买资产，具体方案为： (一) 重大资产置换 此次重大资产置换的置出资产为截至 2018 年 12 月 31 日公司拥有的除保留资产外的全 部资产、业务及负债，置入资产为交易对方持有的山东罗欣的 99.65476%的股权。公司以置 出资产与交易对方合计持有的山东罗欣的 99.65476%股权中等值部分进行置换。 置出资产以坤元资产评估有限公司 2019 年 5 月 28 日出具的《评估报告》所确定的置出 资产截至 2018 年 12 月 31 日的评估价值 90,324.75 万元作为定价依据，经交易各方协商确 定 ...

证券代码：002793 证券简称：罗欣药业 公告编号：2025-097 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、召开会议的基本情况 1、股东会届次：2025年第六次临时股东会 2、股东会的召集人：董事会 3、本次会议的召集、召开符合《中华人民共和国公司法》《深圳证券交易所 股票上市规则》《深圳证券交易所上市公司自律监管指引第1号——主板上市公司 规范运作》等法律、行政法规、部门规章、规范性文件及《公司章程》的有关规 定。 4、会议时间： （1）现场会议时间：2025年11月14日14:00 （2）网络投票时间：通过深圳证券交易所系统进行网络投票的具体时间为 2025 年 11 月 14 日 9:15-9:25，9:30-11:30，13:00-15:00；通过深圳证券交易所互 联网投票系统投票的具体时间为 2025 年 11 月 14 日 9:15 至 15:00 的任意时间。 5、会议的召开方式：本次股东会采取现场投票与网络投票相结合的方式。 罗欣药业集团股份有限公司 关于召开2025年第六次临时股东会的通知 公司将通过深圳证券交易所交易系统和互 ...

证券代码：002793 股票简称：罗欣药业 公告编号：2025-096 罗欣药业集团股份有限公司 第五届董事会第三十二次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 2025 年 10 月 27 日，罗欣药业集团股份有限公司（以下简称"公司"）第 五届董事会第三十二次会议在山东省临沂高新技术产业开发区罗七路管理中心 三楼会议室和上海市浦东新区前滩世贸中心会议室以现场表决和通讯表决相结 合的方式召开。会议通知已于 2025 年 10 月 24 日以电话、专人送达、电子邮件 等方式发出。本次会议应出席董事 6 名，实际出席董事 6 名，公司高级管理人员 列席了会议。公司董事长刘振腾先生主持了本次会议。会议的召集、召开符合《中 华人民共和国公司法》（以下简称"《公司法》"）等法律法规、规范性文件和 《罗欣药业集团股份有限公司章程》（以下简称"《公司章程》"）的规定，合 法有效。 二、董事会会议审议情况 （一）审议通过《关于 2025 年第三季度报告的议案》 董事会编制和审议公司 2025 年第三季度报告的程序符合法律法规和中国 ...

Financial Performance - The company's revenue for Q3 2025 was ¥646,173,009.72, representing a 3.94% increase compared to the same period last year[4] - Net profit attributable to shareholders reached ¥5,231,766.19, a significant increase of 102.96% year-on-year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥2,617,572.43, up 101.48% from the previous year[4] - Total operating revenue for the third quarter was CNY 1,723,415,167.25, a decrease of 8.35% from CNY 1,880,916,973.62 in the previous period[21] - Net profit for the period was CNY 33,559,116.79, compared to a net loss of CNY 317,601,218.57 in the previous period[21] - The net profit attributable to the parent company is ¥22,926,815.63, a decrease from a loss of ¥265,370,489.03 in the previous period[23] - The total comprehensive income amounts to ¥61,556,785.95, compared to a loss of ¥317,388,551.03 in the previous period[23] Cash Flow - The operating cash flow net amount for the year-to-date period was ¥280,115,794.72, reflecting a substantial increase of 272.42%[4] - Operating cash flow generated from activities is ¥280,115,794.72, a significant improvement from a negative cash flow of ¥162,463,515.99 in the previous period[26] - Cash inflow from operating activities totals ¥2,024,224,167.33, up from ¥1,866,257,516.66 in the previous period[26] - Cash outflow from operating activities is ¥1,744,108,372.61, down from ¥2,028,721,032.65 in the previous period[26] - The net cash flow from investing activities is ¥43,012,421.27, an increase from ¥18,363,305.00 in the previous period[26] - The net cash flow from financing activities is -¥292,989,491.23, worsening from -¥97,785,527.09 in the previous period[26] Shareholder Information - Total number of common shareholders at the end of the reporting period is 38,267[11] - The largest shareholder, Shandong Luoxin Holdings, holds 21.79% of shares, totaling 236,955,520 shares, with 138,463,530 shares pledged[11] - The second-largest shareholder, Fang Xiubao, holds 9.22% of shares, totaling 100,294,266 shares[11] - The company approved an employee stock ownership plan allowing for a maximum of 26,027,861 shares at a grant price of 2.03 CNY per share[13] - The company plans to raise up to 842.40 million CNY through a private placement of A-shares, with a maximum issuance of 326,276,545 shares[15] - The company has not disclosed any related party relationships among the top shareholders[12] - The total number of preferred shareholders at the end of the reporting period is not applicable[13] - The company has set aside a reserve of 7,808,358 shares for the employee stock ownership plan[13] - The company will disclose further information regarding the employee stock ownership plan as it progresses[14] - The company has not reported any changes in the top 10 shareholders due to margin trading activities[12] Assets and Liabilities - Total assets at the end of Q3 2025 were ¥3,990,146,666.61, a decrease of 7.98% from the end of the previous year[4] - The company’s total assets decreased to CNY 3,990,146,666.61 from CNY 4,335,978,261.75, a decline of 7.94%[19] - The total liabilities decreased to CNY 2,460,056,368.74 from CNY 2,876,574,008.51, a reduction of 14.51%[19] - The company’s equity attributable to shareholders increased to CNY 1,452,480,831.45 from CNY 1,382,277,279.71, an increase of 5.06%[19] Operational Metrics - The company's basic earnings per share for Q3 2025 was ¥0.0049, up 102.94% year-on-year[4] - Basic earnings per share are ¥0.0216, compared to a loss of ¥0.2486 in the previous period[23] - Diluted earnings per share are ¥0.0213, also an improvement from a loss of ¥0.2486 in the previous period[23] - The weighted average return on equity for the year-to-date period was 1.62%, an increase of 13.37% compared to the same period last year[4] - The company reported a significant increase in other comprehensive income, which rose by 127.12% to ¥49,848,796.21[9] Cost Management - Total operating costs decreased to CNY 1,736,037,629.45 from CNY 2,162,836,623.58, reflecting a reduction of 19.66%[22] - Accounts receivable decreased to CNY 494,084,460.26 from CNY 569,106,113.41, a decline of 13.14%[18] - Inventory levels decreased to CNY 367,856,007.66 from CNY 459,555,606.49, a reduction of 20%[18] - Research and development expenses increased to CNY 63,300,332.23 from CNY 49,206,243.34, marking a rise of 28.66%[22] - The company experienced a 30.69% increase in short-term borrowings, totaling ¥969,785,853.73[9]